EGFR and non-small cell lung carcinoma: In 2013, the US Food and Drug Administration (FDA) approved the first EGFR-tyrosine kinase inhibitor (TKI), erlotinib, in the first-line setting for EGFR-mutant, metastatic NSCLC.